Abstract:In recent studies, vibration-controlled transient elastography (FibroScan) has been reported as an alternative noninvasive approach for measuring liver steatosis and fibrosis. The present study aimed to investigate the feasibility of FibroScan controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) in the detection of increased arterial stiffness in asymptomatic populations in China. A retrospective cohort recruiting 4747 asymptomatic patients with no underlying causes of liver disease and having FibroScan and brachial-ankle pulse wave velocity (baPWV) during wellness check-up was covered. Nonalcoholic fatty liver disease (NAFLD) was defined as a CAP >= 238 dB/m. NAFLD with significant fibrosis was defined as an LSM >= 7.3 kPa in the presence of NAFLD. Increased arterial stiffness was determined as a BaPWV >= 1.4m/second. Among the 4747 study participants, 1596 subjects (33.6%) suffered from increased arterial stiffness. The prevalence of increased arterial stiffness progressively increased across CAP quartiles and LSM quartiles in NAFLD (23.5%, 30.8%, 38.3%, 43.7%, P < .001 and 33.1%, 36.8%, 40.4%, 48.2%, P < .001, respectively). After conventional cardiovascular risk factors were adjusted (age, sex, overweight, diabetes mellitus, hypertension, hypercholesterolemia, and current smoking habits), multivariate logistic regression analysis revealed that CAP (odd ratio [OR] = 1.005; 95% confidence interval [CI]: 1.003-1.006; P < .001), NAFLD (OR = 1.427; 95% CI: 1.212-1.681; P < .001), LSM in NAFLD (OR = 1.073; 95% CI: 1.023-1.125; P = .003), and significant fibrosis in NAFLD (OR = 1.480; 95% CI: 1.090-2.010; P = .012) were independently associated with increased arterial stiffness. Furthermore, in a multivariate logistic regression analysis, OR (95% CI) for the maximal vs. the minimal quartile of CAP was 1.602 (1.268-2.024), and that of LSM in NAFLD was 1.362 (1.034-1.792) after adjustment for the above-mentioned risk factors. Notably, NAFLD and significant fibrosis in NAFLD were significantly correlated only with increased arterial stiffness in subjects without hypertension or diabetes mellitus after adjustment for the above-mentioned risk factors. CAP-defined NAFLD and LSM-defined significant fibrosis in NAFLD showed significant and independent relationships with increased arterial stiffness even after adjustment for conventional cardiovascular risk factors, which can be conducive to stratifying relative risk of subjects having undergone screening assessment for cardiovascular disease.

Relationship Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: Assessment of Latest Evidence

Nonalcoholic Fatty Liver Disease is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study

Identification of Genes and Key Pathways Underlying the Pathophysiological Association Between Nonalcoholic Fatty Liver Disease and Atrial Fibrillation

Usefulness Of Controlled Attenuation Parameter And Liver Stiffness Measurement For Detecting Increased Arterial Stiffness In Asymptomatic Populations In China

Association Between Serum Free Fatty Acid Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study

Association Between Non-Alcoholic Fatty Liver Disease and Arterial Stiffness in the Non-Obese, Non-Hypertensive, and Non-Diabetic Young and Middle-Aged Chinese Population.

ASSA13-10-11 Nonalcoholic Fatty Liver Disease is Associated with Subclinical Atherosclerosis

Relationship Between Non-Alcoholic Fatty Liver Disease and Cardiac Arrhythmia: a Systematic Review and Meta-Analysis

Liver Fibrosis Scores and Atrial Fibrillation Incidence in Heart Failure with Preserved Ejection Fraction

Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients

Linking Atrial Fibrillation with Non-Alcoholic Fatty Liver Disease: Potential Common Therapeutic Targets

Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia

Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups

Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets.

Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis

The Liver-Heart Connection: A Literature Review of Liver Disease as a Risk Factor for Atrial Fibrillation

Abstract 4142577: the Impact of Advanced Liver Fibrosis on Recurrence Following Catheter Radiofrequency Ablation in Atrial Fibrillation Patients

Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis

Research Advances in the Relationship Between Nonalcoholic Fatty Liver Disease and Atherosclerosis

A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation

Noninvasive liver fibrosis markers are independently associated with carotid atherosclerosis risk in patients with nonalcoholic fatty liver disease